Tech Company Financing Transactions
Vivaldi BioSciences Funding Round
On 1/8/2009, Vivaldi BioSciences raised $23 million in Series A financing from Bay City Capital, NGN Capital and New York City Investment Fund.
Transaction Overview
Company Name
Announced On
1/8/2009
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Bay City Capital (Lead Investor) (William Gerber)
NGN Capital (Lead Investor) (Peter Johann)
Proceeds Purpose
Vivaldi intends to use the proceeds from the Series A financing to establish cell-based manufacturing and to file an Investigational New Drug (IND) application to advance its lead vaccine candidate to clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3185-A Rampart Rd. 0922
Fort Collins, CO 80523
USA
Fort Collins, CO 80523
USA
Phone
Website
Email Address
Overview
Vivaldi Biosciences Inc. is developing genetically engineered vaccines with the potential for increased effectiveness in the prevention of common seasonal influenza ("flu") and emergent pandemic flu.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Wick
Chief Scientific Officer
Thomas Muster
VP - Manufacturing
Manfred Reiter
Browse more venture capital transactions:
Prev: 1/8/2009: Sestar Solar Technologies venture capital transaction
Next: 1/8/2009: JibJab Media venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs